These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 8515345)

  • 1. FDA's aseptic processing: proposed regulation.
    Barr DB
    J Parenter Sci Technol; 1993; 47(2):57-9. PubMed ID: 8515345
    [No Abstract]   [Full Text] [Related]  

  • 2. Current practices in the validation of aseptic processing--1992.
    Agalloco J; Akers J
    J Parenter Sci Technol; 1993; 47 Suppl 1():S1-21. PubMed ID: 8515352
    [No Abstract]   [Full Text] [Related]  

  • 3. Viability-based rapid microbiological methods for sterility testing and the need for identification of contamination.
    Moldenhauer J
    PDA J Pharm Sci Technol; 2006; 60(2):81-8. PubMed ID: 16696190
    [No Abstract]   [Full Text] [Related]  

  • 4. The parenteral drug industry: recent findings.
    Fry EM
    J Parenter Sci Technol; 1982; 36(2):55-8. PubMed ID: 7077464
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA's role in drug product recalls.
    Crawford SY
    Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194
    [No Abstract]   [Full Text] [Related]  

  • 6. Application of ISO 9002 and FDA's good manufacturing practices to general chemical manufacturing.
    Kauffman JM; Weiler ED
    Qual Assur; 1992 Jun; 1(3):213-6. PubMed ID: 1344676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDA's response to FDA's "Guideline on sterile drug products produced by aseptic processing".
    Akers JE; Agalloco JP; Carleton FJ; Korczynski MS
    J Parenter Sci Technol; 1988; 42(4):114-7. PubMed ID: 3183865
    [No Abstract]   [Full Text] [Related]  

  • 8. Aseptic processing contamination case studies and the pharmaceutical quality system.
    Friedman RL
    PDA J Pharm Sci Technol; 2005; 59(2):118-26. PubMed ID: 15971544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality control and good manufacturing practices: safety and efficacy of commercial herbals.
    Awang DV
    Food Drug Law J; 1997; 52(3):341-4. PubMed ID: 10343036
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug industry trying to change FDA's slow but sure policy.
    Demkovich LE
    Natl J (Wash); 1979 Jul; 11(29):1211-5. PubMed ID: 10242491
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 12. The FDA's restrictions against prescription drug advertising: more hindrance than help.
    Lorman AJ
    Healthspan; 1991 Nov; 8(10):3-7. PubMed ID: 10114942
    [No Abstract]   [Full Text] [Related]  

  • 13. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 14. The FDA's critical path initiative: a brief introduction.
    Coons SJ
    Clin Ther; 2009 Nov; 31(11):2572-3. PubMed ID: 20110002
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 16. Fake biotech drugs raise concerns.
    Fox JL
    Nat Biotechnol; 2001 Jul; 19(7):603. PubMed ID: 11433258
    [No Abstract]   [Full Text] [Related]  

  • 17. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA's interferon-beta decision reignites orphan debate.
    Marshall A
    Nat Biotechnol; 1999 Apr; 17(4):324-5. PubMed ID: 10207871
    [No Abstract]   [Full Text] [Related]  

  • 19. Current regulatory issues regarding parenteral inspections.
    Avallone H
    J Parenter Sci Technol; 1989; 43(1):3-7. PubMed ID: 2926605
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceutical GMPs.
    Bobrowicz G
    Qual Assur; 1994 Jun; 3(2):138-48. PubMed ID: 7804629
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.